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The diagnosis of Primary Central Nervous System Vasculitis  
 
Claire Rice and Neil Scolding 
 
Abstract 
The diagnosis of Primary Central Nervous System Vasculitis (PCNSV) remains is commonly very 
difficultchallenging in the majority of cases. There are neither specific clinical features nor a classical 
clinical course, and . There are no blood or imaging investigations that can confirm the diagnosis – though 
these play a vital role particularly in excluding other disorders. Contrast catheter cerebral angiography is 
universally accepted to be neither specific nor sensitive, yet remains still underpins the mainstay of 
diagnosis in many published studies There have been few if any changes in treatment in the past four 
decades, and no treatment trials have been conducted. Here we describe an approach to the diagnosis of 
PCNSV, we emphasise the importance of obtaining tissue as part of this approach, and we present for 
discussion a new, binary set of diagnostic criteria, dividing putative cases only into ‘definite’ PCNSV, 
where tissue proof is available, and ‘possible,’ where it is not. We hope that the details of these criteria 
will be modified and significantly improved by discussion amongst others with expertise of in PCNSVthe 
disorder; and but that these (improved) criteria may then be adopted and used as the basis for future 
prospective studies of the clinical features,  and diagnosis and treatment of this difficult and dangerous 





Cerebral vasculitis is a descriptive term rather than a specific disease, referring to inflammation within the 
wall of CNS blood vessels associated with destructive changes, occlusion and infarction1,2. ‘Secondary’ 
CNS vasculitis is where the CNS becomes involved in a systemic vasculitic illness, including but not limited 
to the systemic vasculitides (such as microscopic polyarteritis, or granulomatosis with polyangiitis, 
formerly known eponymously as Wegener's granulomatosis; see Table One). Conversely, in ‘primary’ or 
‘isolated’ vasculitis or angiitis of the CNS (here we will use the term Primary CNS Vasculitis, PCNSV), there 
is little or no overt generalised inflammation. All forms of cerebral vasculitis are relatively rare, but all are 
serious, and potentially life-threatening. 
Secondary CNS vasculitis can be a relatively straightforward diagnosis, often clearly suggested by clinically 
eloquent concurrent or recent disease in more accessible organs – lungs, kidneys, joints, skin etc. 
However, in the case of CNS features occurring when a systemic vasculitic illness has been long present, 
the occasionally complex question can arise of distinguishing secondary CNS involvement of vasculitis 
from iatrogenic immunosuppressant-related opportunistic infection.  
Making a diagnosis of primary CNS vasculitis is, commonly, far more challenging, for several reasons. Its 
rarity means few neurology units have extensive clinical experience of the disorder3. There is no 
diagnostically distinct clinical picture4-10. There are no fail-safe indirect diagnostic tests (including 
contrast/digital subtraction angiography; see below). The brain, and even more the spinal cord, is 
relatively inaccessible and potentially hazardous to biopsy. 
But not least amongst these difficulties of diagnosis is that the criteria upon which a clinical diagnosis of 
PCNSV can be made have not been firmly established or uniformly accepted9,11. There is no real 
consensus on defining the disease – criteria for allowing a diagnosis based on angiography without 
histology are very commonly utilized in published studies and reports9,12-20. Other authors do recommend 
relying on histology10,11,20-23. Such variability of patient inclusion criteria naturally renders interpretation 
difficult and has restricted progress in optimizing treatment. We suggest it would be valuable to divide 
patients into just two diagnostic groups according to the certainty of diagnosis. Here, in addition to 
refining our previously suggested investigational approach to suspected CNS vasculitis6, we propose 
simple draft diagnostic criteria delineating ‘definite’ and ‘possible’ PCNSV. We hope that these criteria can 
be modified by consensus and improved in the future; they could then act as the foundation for more 
detailed prospective analyses, and hopefully facilitate the design of future therapeutic trials.  
 
Clinical features and investigation 
There is no pathognomic clinical picture in PCNSV. Innumerable neurological features occur, depending 
on the site of the vasculature affected, with a clinical course that may be acute or subacute, more 
chronically progressive, or relapsing and remitting4,5,9,21,24,25. Headache is common, as are other non-
specific or non-focal features such as encephalopathy, cognitive change, and generalized seizures; but 
focal neurological abnormalities are also common, including hemispheric, brainstem or spinal deficits, 
movement disorders and optic and other cranial neuropathies. Relatively non-specific systemic features 
of inflammatory disease, such as fever, night sweats, livedo reticularis, and oligoarthropathy may also be 
revealed if specifically sought.  
To aid the initial clinical suspicion and recognition of PCNSV, three distinct presentations encompassing 
this wide diversity of clinical features were previously delineated6,26 :- 
• an acute or subacute encephalopathy, commonly presenting as an acute confusional state, 
progressing to drowsiness and coma; 
• a picture that superficially resembles multiple sclerosis but with atypical features (‘MS-plus’ or 
‘pseudo-MS’) – a relapsing-remitting course including, for example, optic neuropathy and brain 
stem episodes, but also other features less common in multiple sclerosis, such as seizures, severe 
and persisting headaches, encephalopathic episodes, or hemispheric stroke-like episodes; or  
• intracranial mass lesion[s] with headache, drowsiness, focal signs and often raised intracranial 
pressure. 
These are also, of course, non-specific, and may be seen in many neurological disorders, but unless an 
alternative explanation is immediately obvious, their occurrence should lead to PCNSV at least being 
included in the differential diagnosis. 
As with the clinical features, so for investigations: there are no biochemical, immunological or serological 
or imaging investigations that are diagnostic of PCNSV. Non-specific changes are common – a 
normochromic anaemia, and raised plasma viscosity, for example. In a highly informative systematic 
review of published cases, brain MRI was reported to be abnormal in 93.3% of patients (i.e., it can be 
normal), and CSF abnormal in 74.4%. In both cases the abnormalities again were wholly non-specific27. 
Efforts to develop specific MRI-based approaches for demonstrating cerebral vasculitis continue, 
including vessel wall imaging28, but will require rigorous MR-neuropathological correlation before they 
can usefully be applied.  
Therefore, rather than ‘confirming’ PCNSV, the main role of blood tests, CT of chest, abdomen and pelvis, 
CSF examination and MRI scanning is to help exclude alternative inflammatory or autoimmune, infective, 
malignant or other disorders, not uncommonly identifying clinically occult systemic involvement and 
accessible targets for tissue biopsy. Ocular examination, including slit-lamp ophthalmoscopy29, together 
with whole-body CT-PET scanning, can play a similar important role.  
It might be predicted that a disease of blood vessels might be diagnosed by imaging the affected area’s 
vasculature, and cerebral catheter contrast angiography/digital subtraction, CT- and/or MR-angiography 
can indeed show abnormalities. Segmental (often multifocal) narrowing with areas of localized dilatation 
or beading may be seen; single stenotic areas in multiple vessels are said to be more frequent in PCNSV 
than multiple stenotic areas along a single vessel. Formal contrast/digital subtraction angiography 
continues to be associated with a small but significant risk of stroke and, with improvements in MR 
resolution, the likelihood that formal contrast/digital subtraction angiography will add diagnostic 
information above that provided by MR/CT angiography is decreasing. However, precise determination of 
sensitivity and specificity of MR/CT angiography is currently unknown due to lack of histological 
confirmation in published studies30,31 – although unlikely to be greater than that of formal contrast/digital 
subtraction angiography. [CR1] 
As mentioned above, many published studies have depended on catheter angiography in their diagnostic 
confirmation (or exclusion) of PCNSV. However, it has been clear since at least the early 1970s that 
similar, so-called ‘vasculitic’ changes may alternatively be seen in atherosclerotic disease, as a reactive 
change following subarachnoid haemorrhage, in migraine, trauma, hypertension, infections, radiation 
vasculopathy and following illicit drug use22,32. Later, careful studies using histopathological evidence 
show catheter angiography to have both sensitivity and specificity of around 25–35%.9,25,27,33-36  (CT-based 
or MR angiography is even less sensitive.37,38) A normal angiogram therefore cannot exclude PCNSV, while 
a large number of alternative inflammatory, metabolic, malignant or other vasculopathies mimic PCNSV 
on angiography – ‘vasculitic’ changes in fact imply no more than a potential vasculopathy still requiring 
diagnosis. Reversible Cerebral Vasoconstriction Syndrome (RCVS) can represent a particularly difficult 
diagnostic alternative, though an extremely careful and authoritative comparative study has valuably 
highlighted the key clinical and investigational differences.39 MRI based vessel wall imaging may help.40 
 
Cerebral biopsy 
Given the lack of alternative methods of achieving a secure diagnosis, it would appear axiomatic that CNS 
tissue biopsy is required to make a diagnosis of PCNSV. There is, however, a natural reluctance to 
undertake such an invasive procedure, the more so should a particularly eloquent site be the only target 
– dominant temporo-parietal lesions, for example, or those in the brain stem or spinal cord. In addition to 
the potential risks is the question of the imperfect sensitivity, those occasions when neuropathological 
examination shows only ‘non-specific change’ or ‘end-stage tissue damage infarction/gliosis’.  
In our view, a number of considerations, combined with a growing body of observational research 
evidence, very strongly tilt the balance in favour of biopsy. 
First, several studies attest to the relative safety of brain biopsy. The qualifier ‘relative’ is crucial, given the 
life-threatening nature of the disease in question, of some of the alternative diagnostic possibilities, and 
indeed of treatments that may be required if CNS vasculitis is present. In one retrospective study of some 
61 patients biopsied for suspected CNS vasculitis, there were no mortalities and not a single patient 
suffered any permanent ill-effects from the procedure.33 In our study of 56 brain biopsies in cryptogenic 
neurological disease, there were no deaths or permanent deficits41. In a much larger more general brain 
biopsy series, the safety of stereotactic biopsy in over 7000 procedures was assessed: the mortality rate 
was less than 1%, and the morbidity rate was 3.5% though only few of these had permanent disability42. 
(In fact there is some evidence that the mortality and morbidity in biopsying suspected malignancy is 
higher than with cryptogenic neurological disease: in a biopsy meta-analysis restricted to 831 cases of the 
latter, procedure-related mortality was zero.43) It is also becoming clear that even brain stem and spinal 
cord biopsies are less hazardous than previously thought44. Various authorities have presented data 
indicating that the risks of immunosuppressive treatments are greater than those of biopsy13,45.  
Secondly, we now know more of the diagnostic yield and clinical utility of biopsy. The sensitivity is 
considered to lie in the range 50-70%.9,25,33,41 Perhaps more importantly, some 75% of patients receive a 
clear diagnosis – of vasculitis or some other specific pathology, following biopsy.33,41,45 Not uncommonly, 
the alternative, unsuspected diagnosis to emerge from biopsy is infective – 10 out of 61 biopsies in one 
series33, emphasizing the importance of not ‘assuming’ vasculitis and treating with immunosuppressants. 
A very recent meta-analysis suggested no significant difference between frame-based and frameless 
biopsy in terms of diagnostic yield, morbidity, and mortality.46  
Finally, as mentioned in the first sentence, cerebral vasculitis is a descriptive term, not a disease, and it 
has always been anticipated that the term ‘PCNSV’ would comprise a spectrum of specific disorders. 
These are now slowly being dissected and described.47-49 Aβ-related Angiitis (ABRA) is one such disorder, 
likely a sub-type of cerebral amyloid angiopathy (CAA) wherein intramural amyloid depositis have 
triggered an anti-amyloid inflammatory reaction and so vasculitic change. Clearly, only biopsy can 
distinguish ABRA from other forms of PCNSV (and from Cerebral Amyloid Angiopathy-Related 
Inflammation, in which peri-vascular inflammation is apparent in the context of CAA – again perhaps 
triggered by amyloid deposition – but without vasculitis)); similarly, only biopsy can identify the other 
recognized forms of the condition.47-49 In addition, though plainly not an argument that should sway the 
decision in any specific individual case, it is only by looking at tissue that further specific entities we will 
come to understand the likely collection of diseases that underlie PCNSV,47-49 and so help acquire the 
basic knowledge required to develop specific treatmentsbe described. 
Treatment 
The treatment of PCNSV has no direct clinical trial evidence base, and recommendations have changed 
little if at all in several decades. Cyclophosphamide and steroids remain the core of treatment6,10,22,50, the 
former yielding to less toxic immunosuppressants such as azathioprine or methotrexate after an 
induction period generally of 10-12 weeks51 – this approach based principally on evidence from renal 
and/or rheumatological trials where the diagnosis can be robustly determined either serologically or 
following tissue biopsy. Mycophenolate – at least in systemic vasculitis – appears less effective in 
maintaining remission than azathioprine or methotrexate52. There are reports of the potential efficacy of 
rituximab53, but again these are often based on cases lacking histopathological verification, and so are 
open to question. 
 
Proposed diagnostic criteria for PCNSV  
It could be asserted that neither our understanding of the cause[s] of PCNSV, nor approaches to 
diagnosis, nor treatment recommendations, have advanced significantly over the past two or three 
decades or more, perhaps with the exception of the recognition of distinct pathological sub-types. We 
continue to have no randomized treatment trials to provide evidence-based treatment – some of the 
earliest studies of the disease over thirty years ago recommended cyclophosphamide for definite disease, 
and this remains the treatment of choice, based almost entirely on evidence from studies of vasculitis in 
other tissues. PCNSV is an uncommon disorder, but progress in relation to many other diseases of 
comparable rarity has been far greater.  
A major contributing factor to this stasis has been the enormous variation in diagnostic approach – it has 
been estimated that 75% of published cases lack histopathological proof54. Given the consistent range of 
disorders revealed by published biopsy-based studies of cases considered likely cerebral vasculitis, and 
with this, the commensurate low yield of vasculitis (in one study of brain biopsies performed at one 
(major) US academic hospital for consideration of CNS vasculitis within an 8-year window, none of the 14 
patients with clinical and angiographic features thought to be diagnostic for PACNS had vasculitis on 
biopsy55); and given the extensive range of disorders now clearly known to show angiographic changes of 
‘vasculitis’, it is hard to defend the current accepted practice that cases lacking biopsy proof can still be 
labelled as ‘definite’ diagnoses of PCNSV in published series and studies.  
We therefore propose simple, readily applied binary diagnostic criteria (Table 2) – 'possible’ or ‘definite’ 
PCNSV. We have no doubt that the details of these criteria can be modified and significantly improved by 
others who have experience of the disorder, and indeed we hope they will be. But more than this, we 
hope that the principle of histopathological proof may ultimately be accepted generally.  
Vasculitis confined to the CNS was first fully described 60 years ago by Cravioto and Feigin, who 
delineated the classical histopathological features of the disorder, definitively describing it as a “diffuse 
disorder of the central nervous system with some focal accentuation”2. However, it was Calabrese and 
Mallek’s landmark study three decades later that provided a lasting account of the clinical features, 
summarized the angiographic changes, and emphasised the recommendation for high dose 
corticosteroids and cytotoxic drugs, specifically cyclophosphamide, in therapy9. Calabrese and Mallek 
defined the disorder as “an acquired clinical disease characterized by CNS dysfunction that remains 
unexplained following thorough clinical, laboratory, and neurological investigations; appears to be 
unassociated with systemic illness, and yields evidence by cerebral angiography or biopsy of CNS tissue of 
vasculitis confined to the CNS.’ Working from this definition, they also proposed the first diagnostic 
criteria for primary angiitis of the CNS:  (1) a history or clinical findings of an acquired neurologic deficit, 
which remained unexplained after a thorough initial basic evaluation; (2) either classic angiographic or 
histopathologic features of angiitis within the CNS, and (3) no evidence of systemic vasculitis or of any 
other condition to which the angiographic or pathologic features could be secondary9. Ongoing series 
continue to utilize these criteria, or variations of them, allowing diagnosis to rest on angiography without 
biopsy12,13. 
Subsequent studies over the next two decades, however, confirmed that contrast cerebral angiographic 
changes considered typical and diagnostic of vasculitis were not at all specific to the disorder (Table 3). 
Furthermore, many cases of confirmed PCNSV were noted to have normal cerebral angiograms. 
Calabrese himself subsequently confirmed in a direct study that both the diagnostic specificity and the 
positive predictive value of cerebral angiography in this context were less than 30%36. Therefore, so low is 
the specificity that patients with ‘typical’ vasculitic changes can be said not just possibly to have a 
disorder other than PCNSV but statistically more likely to have an alternative disorder.11,27,45,55 
Consequently, many authors have stressed the importance of tissue biopsy to confirm the diagnosis, and 
there have been sporadic proposals of diagnostic criteria that require biopsy proof for a definite 
diagnosis.4,6,11,20,56 Powers11, for example, asserted that “patients without histologic confirmation should 
not be included in case reports, case series, or reviews”.  
Such proposals have, however, been far from universally accepted. In a highly informative 2017 
systematic study of diagnostic test results in PCNSV27, the authors identified 701 published PCNSV cases. 
The diagnosis had been confirmed by biopsy in just 248 of these patients (35.4%). In 99 individuals with 
vasculitis on biopsy, cerebral angiography was normal. Looking at trends over time, the authors also 
reported an increasing diagnostic reliance on angiography and decreasing histopathologic testing over 
the past two decades. They too recommended a ‘definite’ category for diagnosis restricted to those cases 
where tissue proof confirmation was available. Despite these recommendations, current ongoing studies 
and even nationwide prospective surveys continue to include patients without histological confirmation.13 
The draft criteria we propose also require tissue proof for a ‘definite’ categorization. They are more 
rigorous than perhaps any used in any published study of the disease, but we believe this is absolutely 
justified by the range of disorders that mimic PCNSV (particularly angiographically). We propose that 
there is no ‘probable’ category, given the low specificity of contrast angiography. Rather, we suggest that 
all suspected cases lacking histological proof should be described as ‘possible’, and the role of 
angiography therefore implicitly restricted to excluding other specific disorders (moya moya, and 
fibromuscular dysplasia, for example). These new criteria could be used as the basis for retrospective 
literature-based studies of the disease and, we hope in particular, for future prospective studies of the 






• in isolated CNS vasculitis, cerebral angiography without histology is NOT diagnostic  
• CNS biopsy is diagnostically important and relatively safe 
• we propose binary diagnostic criteria, categorizing cases as either "definite" or "possible" – 






TABLE ONE   





















Idiopathic/isolated/primary cerebral/CNS vasculitis 
 [Eale’s disease 
 Cogan’s syndrome] 
 Amyloid-β-related angiitis 
Secondary CNS vasculitis 
Systemic vasculitides 
 Wegener's granulomatosis 
 Churg-Strauss syndrome  
 Behçet's disease 
 Microscopic polyarteritis nodosa 
 Classical PAN 
 Small vessel vasculitis [inc. HSP] 
 Kawasaki disease 
 Giant-cell arteritis 
 Takayasu's arteritis 
Connective tissue diseases 
 Systemic lupus erythematosus 
 Antiphospholipid antibody syndrome   
 Rheumatoid arthritis 
 Sjögren's syndrome 
 Dermatomyositis 
 Systemic  sclerosis 







Infections/immune complexes  
 Viral  
    VZV, HIV 
 Bacteria  
    Syphilis, TB, Mycoplasma, Rickettsia  
 Fungi 
    Aspergillosis, Mucormycosis, Histoplasma    
      Coccidioidomycosis, Candidosis 
 Parasites  
   Cysticercosis, Toxoplasma 
 Secondary cryoglobulins, imm. complex 
    Hep. C, Hep. B, CMV, EBV, parvovirus B19 
    Lyme disease, Malaria 
Malignancy 
 Hodgkin's and non-Hodgkin lymphomas 
 Paraneoplasia 
 Lymphomatoid granulomatosus 
 Malignant angioendotheliomatosis 
 
TABLE TWO 
Proposed criteria for the diagnosis of CNS vasculitis (CNSV) 
 
Definite  
• Clinical presentation suggestive of CNSV with exclusion of alternative possible diagnoses and of primary 
systemic vasculitic syndrome  
• PLUS the presence of positive CNS histology, i.e., biopsy or autopsy showing CNS angiitis (granulomatous, 
lymphocytic, or necrotizing), including evidence of vessel wall damage. 
 
Possible  
• Clinical presentation compatible CNSV with exclusion of alternative possible diagnoses and of primary 
systemic vasculitic syndrome  
• PLUS laboratory and imaging support for CNS inflammation (elevated levels of CSF - protein and/or cells, 
and/or the presence of oligoclonal bands and/or MRI evidence compatible with CNSV), with contrast 
angiographic[CR2]* exclusion of other specific entities 





*Certain disorders – perhaps most particularly moyamoya disease, may require formal contrast angiography for 
definitively diagnosis,57,58 hence our suggesting this rather than MRA or CTA
TABLE THREE 
Conditions that may show ‘vasculitic’ changes on contrast angiography 
 
Intracranial atherosclerosis    Subarachnoid hemorrhage 
CADASIL      Intracerebral hematoma 
Reversible Cerebral Vasoconstriction Syndrome  Migraine  
Antiphospholipid syndrome    Sickle cell disease 
Fibromuscular dysplasia     Alzheimer’s disease 
Intravascular lymphoma     Multiple cerebral emboli [e.g., SBE] 
Herpes zoster arteritis     Marfans’, Ehlers-Danlos syndromes 
Vasospasm [e.g., drug-related]    Severe hypertension 
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